South Africa

Population 2018
58 million

<table>
<thead>
<tr>
<th>Estimate of TB burden*, 2018</th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>301 (215–400)</td>
<td>520 (373–691)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>177 (127–235)</td>
<td>306 (219–406)</td>
</tr>
<tr>
<td>MDR/RR-TB incidence**</td>
<td>11 (7.2–16)</td>
<td>19 (12–28)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>21 (20–23)</td>
<td>37 (35–39)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>42 (30–57)</td>
<td>73 (51–99)</td>
</tr>
</tbody>
</table>

Estimated proportion of TB cases with MDR/RR-TB, 2018

- % tested with rapid diagnostics at time of diagnosis 71%
- % with known HIV status 90%
- % pulmonary 89%
- % bacteriologically confirmed** 70%
- % children aged 0-14 years 7%
- % women 37%
- % men 56%

Total cases notified 235 652

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2018 76% (57–110)

TB patients facing catastrophic total costs

TB case fatality ratio (estimated mortality/estimated incidence), 2018 22% (14–30)

TB/HIV care in new and relapse TB patients, 2018

Patients with known HIV status who are HIV-positive 120 862 59%
- on antiretroviral therapy 104 625 87%

Drug-resistant TB care, 2018

% of bacteriologically confirmed TB cases tested for rifampicin resistance**
- New cases 92%
- Previously treated cases 94%

Laboratory-confirmed cases*

MDR/RR-TB: 13 199, XDR-TB: 553

Patients started on treatment**

MDR/RR-TB: 9 558, XDR-TB: 539

MDR/RR-TB cases tested for resistance to second-line drugs 7 469

Treatment success rate and cohort size

New and relapse cases registered in 2017 77% 240 332
Previously treated cases, excluding relapse, registered in 2017 59% 6 508
HIV-positive TB cases registered in 2017 75% 134 672
MDR/RR-TB cases started on second-line treatment in 2016 54% 11 159
XDR-TB cases started on second-line treatment in 2016 58% 601

TB preventive treatment, 2018

% of HIV-positive people (newly enrolled in care) on preventive treatment 65%
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment 59% (54–65)

TB financing, 2019

National TB budget (US$ millions) 240

Funding source: 87% domestic, 13% international, 0% unfunded

Ranges represent uncertainty intervals
MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
** Calculated for pulmonary cases only
* Includes cases with unknown previous TB treatment history
** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
Generated: 2019-12-10